Novel Bacteriophage YZ2 Shows Promise Against Carbapenem-Resistant Acinetobacter baumannii in Combination Therapy
Key Insights
Researchers isolated and characterized bacteriophage YZ2 (search), which demonstrates potent lytic activity against carbapenem-resistant Acinetobacter baumannii (search) strain ST540 (search), achieving complete bacterial clearance in laboratory models.
The phage exhibits excellent stability across temperatures (4-60°C) and pH ranges (5-11), with a short 20-minute latent period and high burst size of 134 plaque-forming units per infected cell.
Combination therapy with YZ2 and polymyxin B achieved 80% survival rates in Galleria mellonella larvae models, significantly outperforming either treatment alone and demonstrating synergistic antibacterial effects.
Researchers have identified a promising new weapon against one of the world's most dangerous antibiotic-resistant pathogens. A novel bacteriophage designated YZ2 has demonstrated remarkable efficacy against carbapenem-resistant Acinetobacter baumannii (search) (CRAB), offering hope for treating infections that have become increasingly difficult to manage with conventional antibiotics.
The breakthrough comes as A. baumannii infections pose an escalating global health crisis. According to recent data, approximately 90% of deaths related to A. baumannii infections worldwide in 2021 were caused by drug-resistant strains. In China, the CRAB isolation rate has reached approximately 70% and continues rising, while many regions including India, Southeast Asia, the Middle East, and South America report carbapenem-resistant rates exceeding 50%.
Phage Characteristics and Stability
The YZ2 phage was isolated from sewage samples at Yancheng Third People's Hospital (search) using ST540 (search)-type CRAB as the host strain. Electron microscopy revealed the phage's characteristic morphology: an icosahedral capsid measuring 62±3 nm in diameter coupled with a short non-contractile tail of 22±2 nm. Taxonomic analysis confirmed its classification within the Friunavirus genus of the Autographiviridae family.
Stability testing revealed exceptional resilience across clinically relevant conditions. The phage maintained viability between 4°C and 60°C, with activity beginning to decrease only at temperatures above 60°C. pH stability testing showed the phage remained active within the range of 5.0-11.0, though activity diminished at extreme pH levels. Notably, YZ2 demonstrated complete resistance to chloroform exposure, indicating the absence of lipid components in its structure.
Biological Properties and Host Range
Single-cycle replication analysis demonstrated that YZ2 has a 20-minute latent period followed by 30 minutes of active virion release, yielding an average progeny production of 134 plaque-forming units per infected host cell. The optimal multiplicity of infection was determined to be 0.01, at which YZ2 reached its highest titer of 4.9×10⁹ PFU/mL.
Host range studies using 26 clinical CRAB strains revealed that YZ2 specifically infected all ST540 (search) strains and 75% of ST208 (search) strains tested. The phage established highly productive infections with efficiency of plating values ranging from 0.88 to 1.09 in four out of seven ST540-type CRAB strains. Importantly, YZ2 showed no lytic activity against other bacterial species including Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa.
Genomic Analysis and Safety Profile
Complete genome sequencing revealed YZ2 possesses a linear double-stranded DNA genome spanning 40,181 base pairs with a GC content of 37.93%. Functional annotation identified 46 predicted open reading frames, with 30 encoding characterized phage-associated proteins including lytic enzymes, replication and regulatory proteins, and structural components.
Critically, genomic analysis revealed no antibiotic resistance genes, virulence factors, or lysogenic cycle-associated genes, confirming YZ2 as a strictly lytic phage suitable for therapeutic applications. The absence of known virulence determinants makes this phage a promising and safe candidate for antimicrobial therapy.
Synergistic Effects with Antibiotics
Laboratory studies demonstrated significant synergistic effects when YZ2 was combined with polymyxin B. In Galleria mellonella larvae infection models, phage treatment alone achieved survival rates of 100%, 80%, and 60% at multiplicities of infection of 10, 1, and 0.1, respectively. When infected larvae were treated with polymyxin B alone, survival rates reached only 30% at 72 hours.
However, the combination of YZ2 at MOI 0.1 with polymyxin B achieved an 80% larval survival rate, significantly outperforming either treatment alone. These results confirm that phage YZ2 not only effectively inhibits bacterial growth but also enhances therapeutic efficacy when combined with antibiotics.
Clinical Application Success
The therapeutic potential of phage-antibiotic combination therapy was demonstrated in a clinical case involving an elderly patient with extensively drug-resistant A. baumannii pneumonia (search) complicated by acute respiratory distress syndrome (search). After two months of failed antibiotic therapy, the patient received nebulized phage treatment (8×10⁹ PFU twice daily) combined with intravenous polymyxin B, amikacin, and fosfomycin.
Within 8 days of combination therapy, the patient showed remarkable improvement. White blood cell count declined from 19.70×10⁹ to 8.39×10⁹ cells/L, C-reactive protein levels dropped from 203.40 to 67.33 mg/L, and chest X-rays revealed substantial absorption of bilateral pulmonary lesions. Most significantly, five consecutive sputum cultures showed no pathogenic bacterial growth, confirming complete bacterial clearance.
Implications for Future Treatment
The success of YZ2 represents a significant advancement in combating antibiotic-resistant infections. The phage's high specificity for ST540 (search) strains is particularly relevant, as this sequence type represents an emerging lineage that has become increasingly prominent in China and poses serious threats due to its high virulence and drug resistance.
The synergistic mechanism between phages and antibiotics appears multifaceted. Phage YZ2 may degrade bacterial capsules through depolymerase activity, removing physical barriers to antibiotic penetration. Simultaneously, polymyxin B may disrupt bacterial outer membranes, exposing more phage receptors and enhancing viral adsorption and replication efficiency.
While these results are promising, researchers acknowledge limitations including the need for validation in mammalian infection models and optimization of dosing regimens. The narrow host range of YZ2, while minimizing disruption to commensal microbiota, also highlights the need for developing phage cocktails to address the full spectrum of resistant A. baumannii strains.
The development of YZ2 and demonstration of its clinical efficacy marks an important step toward addressing the growing crisis of antibiotic resistance, offering a targeted, effective approach for treating previously intractable infections.